O	0	4	Five
O	5	10	years
O	11	13	of
B-intervention	14	23	letrozole
O	24	32	compared
O	33	37	with
B-control	38	47	tamoxifen
O	48	50	as
O	51	58	initial
O	59	67	adjuvant
O	68	75	therapy
O	76	79	for
O	80	94	postmenopausal
O	95	100	women
O	101	105	with
O	106	115	endocrine
O	115	116	-
O	116	126	responsive
O	127	132	early
O	133	139	breast
O	140	146	cancer
O	146	147	:
O	148	154	update
O	155	157	of
O	158	163	study
O	164	167	BIG
O	168	169	1
O	169	170	-
O	170	172	98
O	172	173	.

O	174	182	Previous
O	183	191	analyses
O	192	194	of
O	195	198	the
O	199	205	Breast
O	206	219	International
O	220	225	Group
O	226	227	(
O	227	230	BIG
O	230	231	)
O	232	233	1
O	233	234	-
O	234	236	98
O	237	241	four
O	241	242	-
O	242	245	arm
O	246	251	study
O	252	260	compared
O	261	268	initial
O	269	276	therapy
O	277	281	with
O	282	291	letrozole
O	292	294	or
O	295	304	tamoxifen
O	305	314	including
O	315	323	patients
O	324	332	randomly
O	333	341	assigned
O	342	344	to
O	345	355	sequential
O	356	365	treatment
O	366	371	whose
O	372	383	information
O	384	387	was
O	388	396	censored
O	397	399	at
O	400	403	the
O	404	408	time
O	409	411	of
O	412	419	therapy
O	420	426	change
O	426	427	.

O	428	435	Because
O	436	440	this
O	441	453	presentation
O	454	457	may
O	458	464	unduly
O	465	472	reflect
O	473	478	early
O	479	485	events
O	485	486	,
O	487	490	the
O	491	498	present
O	499	507	analysis
O	508	510	is
O	511	518	limited
O	519	521	to
O	522	530	patients
O	531	539	randomly
O	540	548	assigned
O	549	551	to
O	552	555	the
O	556	566	continuous
O	567	574	therapy
O	575	579	arms
O	580	583	and
O	584	592	includes
O	593	601	protocol
O	601	602	-
O	602	609	defined
O	610	617	updated
O	618	625	results
O	625	626	.

B-total-participants	627	631	Four
I-total-participants	632	640	thousand
I-total-participants	641	645	nine
I-total-participants	646	653	hundred
I-total-participants	654	660	twenty
I-total-participants	660	661	-
I-total-participants	661	664	two
O	665	667	of
O	668	671	the
O	672	673	8
O	673	674	,
O	674	677	028
B-eligibility	678	692	postmenopausal
I-eligibility	693	698	women
I-eligibility	699	703	with
I-eligibility	704	712	receptor
I-eligibility	712	713	-
I-eligibility	713	721	positive
I-eligibility	722	727	early
I-eligibility	728	734	breast
I-eligibility	735	741	cancer
O	742	750	randomly
O	751	759	assigned
O	760	761	(
O	761	767	double
O	767	768	-
O	768	773	blind
O	773	774	)
O	775	777	to
O	778	781	the
O	782	785	BIG
O	786	787	1
O	787	788	-
O	788	790	98
O	791	796	trial
O	797	801	were
O	802	810	assigned
O	811	813	to
O	814	815	5
O	816	821	years
O	822	824	of
O	825	835	continuous
O	836	844	adjuvant
O	845	852	therapy
O	853	857	with
O	858	864	either
O	865	874	letrozole
O	875	877	or
O	878	887	tamoxifen
O	887	888	;
O	889	892	the
O	893	902	remainder
O	903	905	of
O	906	911	women
O	912	916	were
O	917	925	assigned
O	926	928	to
O	929	936	receive
O	937	940	the
O	941	947	agents
O	948	950	in
O	951	959	sequence
O	959	960	.

B-outcome-Measure	961	968	Disease
I-outcome-Measure	968	969	-
I-outcome-Measure	969	973	free
I-outcome-Measure	974	982	survival
I-outcome-Measure	983	984	(
I-outcome-Measure	984	987	DFS
I-outcome-Measure	987	988	)
O	989	992	was
O	993	996	the
O	997	1004	primary
O	1005	1008	end
O	1009	1014	point
O	1014	1015	.

O	1016	1018	At
O	1019	1020	a
O	1021	1027	median
O	1028	1034	follow
O	1034	1035	-
O	1035	1037	up
O	1038	1042	time
O	1043	1045	of
O	1046	1048	51
O	1049	1055	months
O	1055	1056	,
O	1057	1059	we
O	1060	1068	observed
B-iv-bin-abs	1069	1072	352
B-outcome	1073	1076	DFS
I-outcome	1077	1083	events
O	1084	1089	among
B-intervention-participants	1090	1091	2
I-intervention-participants	1091	1092	,
I-intervention-participants	1092	1095	463
O	1096	1101	women
O	1102	1111	receiving
O	1112	1121	letrozole
O	1122	1125	and
B-cv-bin-abs	1126	1129	418
O	1130	1136	events
O	1137	1142	among
B-control-participants	1143	1144	2
I-control-participants	1144	1145	,
I-control-participants	1145	1148	459
O	1149	1154	women
O	1155	1164	receiving
O	1165	1174	tamoxifen
O	1174	1175	.

O	1176	1180	This
O	1181	1190	reflected
O	1191	1193	an
O	1194	1196	18
O	1196	1197	%
O	1198	1207	reduction
O	1208	1210	in
O	1211	1214	the
B-outcome	1215	1219	risk
I-outcome	1220	1222	of
I-outcome	1223	1225	an
I-outcome	1226	1231	event
O	1232	1233	(
O	1233	1239	hazard
O	1240	1245	ratio
O	1245	1246	,
O	1247	1248	0
O	1248	1249	.
O	1249	1251	82
O	1251	1252	;
O	1253	1255	95
O	1255	1256	%
O	1257	1259	CI
O	1259	1260	,
O	1261	1262	0
O	1262	1263	.
O	1263	1265	71
O	1266	1268	to
O	1269	1270	0
O	1270	1271	.
O	1271	1273	95
O	1273	1274	;
O	1275	1276	P
O	1277	1278	=
O	1279	1280	.
O	1280	1283	007
O	1283	1284	)
O	1284	1285	.

O	1286	1288	No
O	1289	1299	predefined
O	1300	1307	subsets
O	1308	1314	showed
O	1315	1327	differential
O	1328	1335	benefit
O	1335	1336	.

B-outcome	1337	1344	Adverse
I-outcome	1345	1351	events
O	1352	1356	were
O	1357	1364	similar
O	1365	1367	to
O	1368	1376	previous
O	1377	1384	reports
O	1384	1385	.

O	1386	1394	Patients
O	1395	1397	on
O	1398	1407	tamoxifen
O	1408	1419	experienced
O	1420	1424	more
B-outcome	1425	1439	thromboembolic
I-outcome	1440	1446	events
O	1446	1447	,
B-outcome	1448	1459	endometrial
I-outcome	1460	1469	pathology
O	1469	1470	,
B-outcome	1471	1474	hot
I-outcome	1475	1482	flashes
O	1482	1483	,
B-outcome	1484	1489	night
I-outcome	1490	1496	sweats
O	1496	1497	,
O	1498	1501	and
B-outcome	1502	1509	vaginal
I-outcome	1510	1518	bleeding
O	1518	1519	.

O	1520	1528	Patients
O	1529	1531	on
O	1532	1541	letrozole
O	1542	1553	experienced
O	1554	1558	more
B-outcome	1559	1563	bone
I-outcome	1564	1573	fractures
O	1573	1574	,
B-outcome	1575	1585	arthralgia
O	1585	1586	,
B-outcome	1587	1590	low
I-outcome	1590	1591	-
I-outcome	1591	1596	grade
I-outcome	1597	1617	hypercholesterolemia
O	1617	1618	,
O	1619	1622	and
B-outcome	1623	1637	cardiovascular
I-outcome	1638	1644	events
O	1645	1650	other
O	1651	1655	than
O	1656	1664	ischemia
O	1665	1668	and
O	1669	1676	cardiac
O	1677	1684	failure
O	1684	1685	.

O	1686	1689	The
O	1690	1697	present
O	1698	1705	updated
O	1706	1714	analysis
O	1714	1715	,
O	1716	1721	which
O	1722	1725	was
O	1726	1733	limited
O	1734	1736	to
O	1737	1745	patients
O	1746	1748	on
O	1749	1760	monotherapy
O	1761	1765	arms
O	1766	1768	in
O	1769	1772	BIG
O	1773	1774	1
O	1774	1775	-
O	1775	1777	98
O	1777	1778	,
O	1779	1785	yields
O	1786	1793	results
O	1794	1801	similar
O	1802	1804	to
O	1805	1810	those
O	1811	1815	from
O	1816	1819	the
O	1820	1828	previous
O	1829	1836	primary
O	1837	1845	analysis
O	1846	1849	but
O	1850	1854	more
O	1855	1863	directly
O	1864	1874	comparable
O	1875	1879	with
O	1880	1887	results
O	1888	1892	from
O	1893	1898	other
O	1899	1905	trials
O	1906	1908	of
O	1909	1919	continuous
O	1920	1927	therapy
O	1928	1933	using
O	1934	1935	a
O	1936	1942	single
O	1943	1952	endocrine
O	1953	1958	agent
O	1958	1959	.
